Healthcare Webinars

In preparation for the introduction of the new Aged Care Act and strengthened Quality Standards, this webinar will introduce the Commission’s new draft Regulatory Strategy that describes how we will deliver on our commitment to safeguard and protect older people, and how we hold providers and workers to account. It will advise providers and workers what we expect from them, and how we will engage with them. Importantly, it also tells older people and their families, as well as providers and workers what they can expect from us.SpeakersJanet Anderson, PSM, Aged Care Quality and Safety CommissionerLisa Peterson, PSM, Deputy Commissioner, Sector Capability and Regulatory Strategy, Aged Care Quality and Safety CommissionLouise Macleod, Complaints Commissioner, Aged Care Quality and Safety CommissionPeter Edwards, Executive Director, Compliance Management Group, Aged Care Quality and Safety CommissionEmma Jobson, Executive Director, Regulatory Policy and Intelligence, Aged Care Quality and Safety CommissionAnthony Speed, Executive Director, Quality Assessment and Monitoring, Aged Care Quality and Safety Commission

Delve into the innovative journey of developing a new medicine using the Inhaled Oxytocin project as a case study. This technology was devised and initially developed at Monash University and is now entering clinical development in collaboration with GSK and philanthropic funding partners. Our guest speaker, Associate Professor Pete Lambert, from the Department of Pharmacy and Pharmaceutical Sciences at Monash University, brings over 20 years of expertise in pharmaceutical product development.KEY TOPICS:- Development pathway for new medicines- Proof of concept- Phase 2 clinical development- Running not-for-profit programs- Partnering with pharmaceuticalsSPEAKER:Pete Lambert, Pharmacy and Pharmaceutical Sciences, Monash UniversityABOUT PETE LAMBERT:Peter is a pharmaceutical scientist and programme director specialising in global health R&D. He currently leads the inhaled oxytocin project seeking to develop a novel oxytocin product to better manage postpartum haemorrhage in low resource settings.He is also a co-coordinator of the Global Health Therapeutic Program Area at Monash Institute of Pharmaceutical Sciences.Originally trained as a pharmacist, Pete has 20+ years experience in product development in the pharmaceutical industry.

Join us for an insightful webinar where we will delve into the comprehensive vision of the ODIN project. This session will provide an in-depth look at the strategies developed to effectively integrate change management practices in hospital settings, alongside the barriers and challenges faced when introducing innovations into hospital processes.Key Details:Date: 10th JulyTime: Between 12pm and 1pm CET (60 minutes max)Presenter: MSc. Beatriz MerinoPresenter Profile: MSc. Beatriz Merino is a Biomedical Engineer specializing in Medical Images, with credentials from the Technical University of Madrid. She holds a Master’s in Biomedical Engineering with a focus on management and innovation in healthcare technologies, as well as a Master of Business Administration. Since 2017, she has been a researcher and project manager at the Life Supporting Technologies (LifeSTech) research group. Her research focuses on ICT in the Health domain and active and healthy aging, particularly chronic disease management and diabetes.Webinar Highlights:Detailed exploration of the ODIN project’s vision.Insights into the development and integration of change management practices in hospitals.Discussion of the barriers and challenges in implementing innovations in hospital processes.Don’t miss this opportunity to gain valuable knowledge and perspectives on managing change and innovation within the healthcare sector.

Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis (EAA), is an immune-mediated interstitial lung disease triggered by inhaled antigens such as molds, bird feathers, and agricultural dusts. Often linked to working conditions, HP is a disease of many faces, from inflammatory self-limiting disease to relapsing or progressive inflammatory disease and chronic fibrotic disease. As there does not exist a single, universal diagnostic criterion, HP is diagnosed by a combination of findings established through clinical history, including imaging, histopathology, pulmonary function testing, bronchoscopy, and serology. With the rise of automated immunoassays capable of quantitatively measuring specific IgG to common HP antigens, an expanded diagnostic can be used to detect the potential triggering antigen.This webinar delves into the pathophysiology of HP, highlights the diagnostic criteria according to the current guidelines, and emphasizes the utility of specific IgG determination and the importance of cutoff values in HP.Key learning objectives:Describe the pathophysiology of hypersensitivity pneumonitisExplain the diagnostic criteria used to establish HPDiscuss the value of serology in HPAccreditation statementSelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.Presenters: Dora Wells (Editorial Team, SelectScience) and Dr. Johannes Grosch (Clinical Expert, Siemens Healthineers).

Skin, Healing and Immune Response Chairperson Prof. Andrea R. Genazzani. Speakers: Prof. Frederick Naftolin Estrogens and Skin Prof. Mark Brincat The effects of Hormonal Contraception including COC, And HRT on Collagen turnover.

Join our expert speakers as we discuss birth trauma; the definition, the impacts on physical and mental health, and how to get help.Birth trauma has been hitting the headlines, with thousands of women coming forward to describe the debilitating psychological, physical, and societal impacts of traumatic births on their lives. 30,000 women develop post-traumatic stress disorder (PTSD) every year because of a frightening, stressful or distressing events related to childbirth. Many also find themselves recovering from birth injuries which can be life altering, resulting in chronic pain, incontinence and infertility.Join our expert speakers as we explore this subject in more detail, answering the key questions; What are the main causes of birth trauma? What are the psychological and physical impacts? And most importantly, what support is available for the people affected?Have a question for one of our speakers? Email events@wellbeingofwomen.org.uk before the event and they’ll do their best to answer your questions during the session.

Summary: We identified 71 patients with AdvSM (aggressive SM [ASM], SM with an associated hematologic neoplasm [SM-AHN, e.g., acute myeloid leukemia, SM-AML], mast cell leukemia [MCL]) in two national registries (DRST/GREM) who received an allogeneic hematopoietic cell transplantation (alloHCT) performed in Germany from 1999–2021. Median overall survival (OS) of ASM/SM-AHN (n = 30, 45%), SM-AML (n = 28, 39%) and MCL ± AHN (n = 13, 19%) was 9.0, 3.3 and 0.9 years (P = 0.007). Improved median OS was associated with response of SM (17/41, 41%; HR 0.4 [0.2–0.9], P = 0.035) and/or of AHN (26/43, 60%, HR 0.3 [0.1–0.7], P = 0.004) prior to alloHCT. Adverse predictors for OS included absence of KIT D816V (10/61, 16%, HR 2.9 [1.2–6.5], P < 0.001) and a complex karyotype (9/60, 15%, HR 4.2 [1.8–10.0], P = 0.016). HLA-match, conditioning type or transplantation at centers reporting aboveaverage alloHCTs (≥7) had no impact on OS. Taking into account competing events at years 1, 3 and 5, relapse-related mortality and non-relapse mortality rate were 15%/23%, 20%/30% and 23%/35%, respectively. Irrespective of subtype, subsequent treatment response was achieved in 13/30 (43%) patients and was highest on midostaurin/avapritinib (7/9, 78%). We conclude that outcome of alloHCT in AdvSM is more affected by disease phenotype and treatment response prior to transplant than by transplant characteristics.Speakers: Damaj Gandhi, Laurent Francesco and Onida Andreas Reiter.

In this Webcast, we will confront the critical issue of provider mental health and breaking the silence on topics many avoid. Moving beyond the outdated mindset of "suck it up and move on," we embrace the modern view that it's okay to not be okay. But what happens when you or a colleague truly aren't okay? How do you respond when someone admits they are struggling, considering suicide, or feeling overwhelmed? Have you fostered an environment where such honesty is supported, or are these confessions still trapped, turning colleagues into statistics?Join us as we dive into these uncomfortable but crucial conversations and explore effective resources to effectively support your peers and most importantly yourself.... while earning 1.0 hour of CAPCE-accredited CE. Let's recognize that all of us, despite our Type-A personalities and reliance on caffeine, are human beings in need of support.

Explore how linked electronic health record (EHR) and social drivers of health (SDOH) data are accelerating the identification of health disparities for Type 2 diabetes, Alzheimer’s disease, and heart disease treatments.Through research vignettes highlighting GLP-1s, lecanemab, and TAVR/SAVR procedures, experts from Truveta will demonstrate how complete, clean, and timely regulatory-grade EHR data is shedding light on inequities in therapy access and outcomes. The findings, which rely on linked, patient-level SDOH data, highlight noteworthy variability in treatment patterns based on race, ethnicity, income, familial support, urban/rural status, and more.What you will learn:Learn how clinical expert-led AI is unlocking data hidden within unstructured EHR and SDOH data to enable novel real-world researchDelve into recent studies highlighting trends in real-world use of popular treatmentsGain ideas for leveraging linked EHR and SDOH data to identify and address healthcare disparities

One of the biggest challenges the pharma industry continues to face today is the failure of drug candidates due to unexpected adverse reactions. Late-stage clinical attrition for safety reasons represents a high risk in terms of patient safety and cost. Early anticipation of safety issues enables informed decisions.In this session we will present how OFF-X's analytic tools and curated data from a broad range of sources can help de-risk drug development.Agenda:Challenges the pharma industry continues to face today How the safety intelligence tool OFF-X can help de-risk drug developmentDrug - SemagacestatTarget – BTK inhibitorsTarget- 4-1BB activatorsSummaryQ&ASpeaker: Kinsi Oberoi, Senior Solution Consultant​